Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

The expanding family of dendritic cell subsets.

Ueno H, Palucka AK, Banchereau J.

Nat Biotechnol. 2010 Aug;28(8):813-5. doi: 10.1038/nbt0810-813. No abstract available.

PMID:
20697407
2.

Processing and presentation of antigens by dendritic cells: implications for vaccines.

Bhardwaj N.

Trends Mol Med. 2001 Sep;7(9):388-94. Review.

PMID:
11530333
3.

Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells.

Inaba K, Young JW, Steinman RM.

J Exp Med. 1987 Jul 1;166(1):182-94.

4.

Neonatal adaptive immunity comes of age.

Adkins B, Leclerc C, Marshall-Clarke S.

Nat Rev Immunol. 2004 Jul;4(7):553-64. No abstract available.

PMID:
15229474
5.

Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression.

McLellan AD, Kapp M, Eggert A, Linden C, Bommhardt U, Bröcker EB, Kämmerer U, Kämpgen E.

Blood. 2002 Mar 15;99(6):2084-93.

6.

CTL priming by CD8(+) and CD8(-) dendritic cells in vivo.

Ruedl C, Bachmann MF.

Eur J Immunol. 1999 Nov;29(11):3762-7.

7.

Strategies for improved antigen delivery into dendritic cells.

Rea D, Johnson ME, Havenga MJ, Melief CJ, Offringa R.

Trends Mol Med. 2001 Mar;7(3):91-4.

PMID:
11286763
8.

Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.

Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A, Mackensen A.

Clin Cancer Res. 2000 May;6(5):1997-2005.

9.

[The outlook for CD1d-activated dendritic cell immunotherapy].

Nieda M, Juji T.

Rinsho Ketsueki. 1999 Jun;40(6):472-5. Japanese. No abstract available.

PMID:
10422281
10.

Induction of CTL and nonpolarized Th cell responses by CD8alpha(+) and CD8alpha(-) dendritic cells.

Schlecht G, Leclerc C, Dadaglio G.

J Immunol. 2001 Oct 15;167(8):4215-21.

11.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
12.

Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP.

Obstet Gynecol. 2000 Sep;96(3):422-30.

PMID:
10960637
13.
14.

Immunotherapy of cancer using dendritic cells.

Morse MA, Lyerly HK.

Cytokines Cell Mol Ther. 1998 Mar;4(1):35-44. Review.

PMID:
9557215
15.

Dendritic cell based personalized immunotherapy based on cancer antigen research.

Kawakami Y, Fujita T, Kudo C, Sakurai T, Udagawa M, Yaguchi T, Hasegawa G, Hayashi E, Ueda Y, Iwata T, Wang Q, Okada S, Tsukamoto N, Matsuzaki Y, Sumimoto H.

Front Biosci. 2008 Jan 1;13:1952-8. Review.

PMID:
17981682
16.

HOZOTs, novel human regulatory T-cell lines, exhibit helper or suppressor activities depending on dendritic cell or anti-CD3 stimulation.

Sugimoto A, Suzuki M, Otani T, Okochi A, Takeuchi M, Yamasaki F, Nakamura S, Kibata M.

Exp Hematol. 2009 Dec;37(12):1454-63. doi: 10.1016/j.exphem.2009.10.002. Epub 2009 Oct 9.

PMID:
19819295
17.
18.

Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1.

Jirmo AC, Nagel CH, Bohnen C, Sodeik B, Behrens GM.

J Immunol. 2009 Jan 1;182(1):283-92.

19.

CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

den Haan JM, Lehar SM, Bevan MJ.

J Exp Med. 2000 Dec 18;192(12):1685-96.

20.
Items per page

Supplemental Content

Write to the Help Desk